Citius Pharmaceuticals Inc (CTXR) — Cash Flow-to-Debt Ratio
Citius Pharmaceuticals Inc (CTXR) has a Cash Flow-to-Debt Ratio of -0.02x as of March 2026, meaning its operating cash flow of $-1.30 Million could theoretically repay 0% of its total liabilities ($63.46 Million) in one year. Explore Citius Pharmaceuticals Inc operating cash flow efficiency to assess how effectively this company generates cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Citius Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2011–2025)
Historical debt coverage capacity for Citius Pharmaceuticals Inc across 15 annual periods. Also explore CTXR asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Citius Pharmaceuticals Inc (2011–2025)
Year-by-year debt coverage analysis for Citius Pharmaceuticals Inc. For market capitalisation and broader financial context, see CTXR company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.50x | $-26.55 Million | $53.41 Million | ▲ +25.0% |
| 2024 | -0.66x | $-28.20 Million | $42.55 Million | ▲ +72.2% |
| 2023 | -2.39x | $-29.06 Million | $12.18 Million | ▲ +11.1% |
| 2022 | -2.68x | $-28.36 Million | $10.57 Million | ▼ -6.7% |
| 2021 | -2.51x | $-24.25 Million | $9.65 Million | ▼ -50.0% |
| 2020 | -1.68x | $-16.93 Million | $10.10 Million | ▲ +37.9% |
| 2019 | -2.70x | $-12.44 Million | $4.61 Million | ▲ +24.0% |
| 2018 | -3.55x | $-11.32 Million | $3.18 Million | ▼ -10.1% |
| 2017 | -3.23x | $-7.97 Million | $2.47 Million | ▼ -183.6% |
| 2016 | -1.14x | $-5.90 Million | $5.18 Million | ▲ +34.3% |
| 2015 | -1.73x | $-2.39 Million | $1.38 Million | ▼ -465.1% |
| 2014 | -0.31x | $-705.05K | $2.30 Million | ▲ +78.1% |
| 2013 | -1.40x | $-20.60K | $14.69K | ▼ -217.2% |
| 2012 | -0.44x | $-20.32K | $45.98K | ▲ +48.8% |
| 2011 | -0.86x | $-20.78K | $24.05K | — |